enGene Therapeutics Inc. (ENGN)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $161.51M
Last updated: Nov 17, 2026 at 11:05 AM ET
enGene Therapeutics Inc. (ENGN) Financials: Revenue, Profit and Cash Flow
enGene Therapeutics reported revenue of $0 for the fiscal year ended Oct 31, 2025. That year, net income was -$117.30M, operating cash flow was -$99.24M and free cash flow was -$100.72M. The quarter ended Jul 31, 2026 had revenue of $0 and net income of -$32.50M.
Revenue and Margins
The company reported no revenue in the fiscal year ended Oct 2025, with an operating loss of $123.17M.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Oct 2025 | $0 | N/A | N/A | N/A | N/A |
| Oct 2024 | $0 | N/A | N/A | N/A | N/A |
| Oct 2023 | $0 | N/A | N/A | N/A | N/A |
| Oct 2022 | $0 | N/A | N/A | N/A | N/A |
| Oct 2021 | $0 | N/A | N/A | N/A | N/A |
| Oct 2020 | $0 | N/A | N/A | N/A | N/A |
Income Statement
In the fiscal year ended Oct 2025, the net loss widened from the year before. In the quarter ended Jul 2026, the net loss widened from the same quarter a year earlier.
Annual
| Line item | Oct 2025 | Oct 2024 | Oct 2023 | Oct 2022 | Oct 2021 | Oct 2020 |
|---|---|---|---|---|---|---|
| Research and development | $94.48M | $38.31M | $16.46M | $15.47M | $12.46M | $10.61M |
| Operating income | -$123.17M | -$62.30M | -$26.06M | -$19.43M | -$15.87M | -$13.85M |
| Net income | -$117.30M | -$55.14M | -$99.92M | -$24.46M | -$23.44M | -$15.07M |
| EBITDA | N/A | -$62.21M | N/A | N/A | N/A | -$12.90M |
Quarterly
| Line item | Jul 2026 | Apr 2026 | Jan 2026 | Oct 2025 | Jul 2025 | Apr 2025 | Jan 2025 | Oct 2024 | Jul 2024 | Apr 2024 | Jan 2024 | Oct 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $480.00K | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | -$171.00K | $0 | $0 | $0 | $240.00K | $0 | $0 | $0 | N/A |
| Operating income | -$34.01M | -$31.97M | -$31.18M | -$39.48M | -$29.95M | -$27.12M | -$26.61M | -$17.45M | -$16.76M | -$17.31M | -$10.77M | -$10.44M |
| Net income | -$32.50M | -$30.23M | -$29.75M | -$37.88M | -$28.99M | -$25.82M | -$24.62M | -$15.30M | -$14.15M | -$14.98M | -$10.71M | -$82.50M |
Balance Sheet
As of Oct 2025, cash and equivalents exceeded total debt of $23.33M by $26.83M.
Annual
| Line item | Oct 2025 | Oct 2024 | Oct 2023 | Oct 2022 | Oct 2021 | Oct 2020 |
|---|---|---|---|---|---|---|
| Total assets | $221.47M | $311.17M | $86.96M | $132.04M | $131.45M | N/A |
| Current assets | $201.39M | $247.36M | $85.44M | $511.80K | $1.57M | N/A |
| Cash and equivalents | $50.15M | $173.00M | $81.52M | $314.15K | $1.07M | N/A |
| Total liabilities | $53.76M | $38.56M | $14.47M | $4.62M | $4.05M | N/A |
| Short-term debt | $8.00M | $699.00K | $562.00K | $1.26M | $1.05M | N/A |
| Long-term debt | $15.32M | $22.47M | $9.22M | $30.84M | $3.05M | N/A |
| Shareholder equity | $167.71M | $272.61M | $72.49M | $127.42M | $127.39M | N/A |
Quarterly
| Line item | Jul 2026 | Apr 2026 | Jan 2026 | Oct 2025 | Jul 2025 | Apr 2025 | Jan 2025 | Oct 2024 | Jul 2024 | Apr 2024 | Jan 2024 | Oct 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $288.32M | $307.52M | $337.11M | $221.47M | $245.55M | $266.65M | $285.93M | $311.17M | $266.88M | $273.53M | $93.42M | $86.96M |
| Total liabilities | $58.03M | $52.36M | $55.57M | $53.76M | $44.88M | $39.36M | $35.98M | $38.56M | $36.55M | $30.56M | $31.04M | $14.47M |
| Cash and equivalents | $41.02M | $29.83M | $36.61M | $50.15M | $32.62M | $57.55M | $62.35M | $173.00M | $257.68M | $264.81M | $85.65M | $81.52M |
| Shareholder equity | $230.29M | $255.17M | $281.55M | $167.71M | $200.67M | $227.29M | $249.95M | $272.61M | $230.33M | $242.97M | $62.38M | $72.49M |
Cash Flow
Operating cash flow was negative in the fiscal year ended Oct 2025.
Annual
| Line item | Oct 2025 | Oct 2024 | Oct 2023 | Oct 2022 | Oct 2021 | Oct 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$99.24M | -$48.28M | -$24.74M | -$17.59M | -$15.98M | -$13.06M |
| Capital expenditures | $1.49M | $925.00K | $318.00K | $153.00K | $248.00K | $192.00K |
| Free cash flow | -$100.72M | -$49.21M | -$25.06M | -$17.75M | -$16.23M | -$13.25M |
| Investing cash flow | -$25.14M | -$125.95M | -$318.00K | -$153.00K | -$247.00K | -$192.00K |
| Financing cash flow | $1.52M | $265.72M | $86.15M | $27.97M | $22.52M | $12.85M |
Quarterly
| Line item | Jul 2026 | Apr 2026 | Jan 2026 | Oct 2025 | Jul 2025 | Apr 2025 | Jan 2025 | Oct 2024 | Jul 2024 | Apr 2024 | Jan 2024 | Oct 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$18.95M | -$30.50M | -$28.90M | -$24.96M | -$25.63M | -$22.95M | -$25.70M | -$19.57M | -$7.18M | -$14.16M | -$7.37M | -$6.78M |
| Capital expenditures | N/A | $98.00K | $153.00K | $437.00K | $704.00K | $45.00K | $299.00K | $238.00K | $2.00K | $179.00K | $506.00K | $138.00K |
| Free cash flow | N/A | -$30.60M | -$29.06M | -$25.40M | -$26.34M | -$22.99M | -$26.00M | -$19.81M | -$7.18M | -$14.34M | -$7.88M | -$6.91M |
Frequently Asked Questions About ENGN
What is enGene Therapeutics' annual revenue?
enGene Therapeutics reported revenue of $0 for the fiscal year ended Oct 31, 2025.
Is enGene Therapeutics profitable?
No. enGene Therapeutics reported net income of -$117.30M for the fiscal year ended Oct 31, 2025.
How much free cash flow does ENGN generate?
For the fiscal year ended Oct 31, 2025, operating cash flow of -$99.24M minus capital expenditures of $1.49M produced free cash flow of -$100.72M.
How much debt does enGene Therapeutics have?
The balance sheet dated Oct 31, 2025 reported long-term debt of $15.32M, short-term debt of $8.00M and cash and equivalents of $50.15M.
ENGN pages: Overview, Earnings, Forecast, Financials, Competitors